AP NEWS

Homozygous Familial Hypercholesterolemia (HoFH) Pipeline Review, H1 2018 - Therapeutics Development & Assessment, Key Companies Involved, Drug Profiles - ResearchAndMarkets.com

June 11, 2018

DUBLIN--(BUSINESS WIRE)--Jun 11, 2018--The “Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Review, H1 2018” report has been added to ResearchAndMarkets.com’s offering.

This latest pipeline guide provides comprehensive information on the therapeutics under development for Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Homozygous Familial Hypercholesterolemia (HoFH) and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 3, 5, 1, 2 and 1 respectively.

Companies Mentioned

Akcea Therapeutics Inc CymaBay Therapeutics Inc Daewoong Co Ltd Gemphire Therapeutics Inc LipimetiX Development Inc Madrigal Pharmaceuticals Inc Regeneron Pharmaceuticals Inc RegenxBio Inc The Medicines Company

Key Topics Covered

Introduction Report Coverage Homozygous Familial Hypercholesterolemia (HoFH) - Overview Homozygous Familial Hypercholesterolemia (HoFH) - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Homozygous Familial Hypercholesterolemia (HoFH) - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Homozygous Familial Hypercholesterolemia (HoFH) - Companies Involved in Therapeutics Development Homozygous Familial Hypercholesterolemia (HoFH) - Drug Profiles Homozygous Familial Hypercholesterolemia (HoFH) - Dormant Projects Homozygous Familial Hypercholesterolemia (HoFH) - Discontinued Products Homozygous Familial Hypercholesterolemia (HoFH) - Product Development Milestones Featured News & Press Releases

For more information about this report visit https://www.researchandmarkets.com/research/t2hlrv/homozygous?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180611005993/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Cardiovascular Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH CARDIOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/11/2018 02:11 PM/DISC: 06/11/2018 02:11 PM

http://www.businesswire.com/news/home/20180611005993/en

AP RADIO
Update hourly